Caplacizumab is a von Willebrand factor (vWF)-directed antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP). Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression
Mechanism of action
Caplacizumab acts by targetting the A1 domain of the ultra-large von Willebrand factor which in order inhibits the interaction with the glycoprotein Ib-IX-V receptor in the platelets. Caplacizumab binds to von Willebrand factor with an affinity of 8.5 nM, thus it is very target specific.[5305] The blockage of the von Willebrand factor prevents the interaction between the von Willebrand factor and the platelets, hence, preventing platelet aggregation.[rx]
In vitro studies have shown a caplacizumab-driven complete inhibition of platelet aggregation and in phase II clinical trials, it was shown to reduce the activity of the von Willebrand factor by 20% from treatment day 1 until treatment day 30. The level of von Willebrand factor in the plasma was also significantly reduced due to the clearance of the von Willebrand-caplacizumab complex.[rx]
In phase III clinical trials, more than 50% of the tested individuals reached a platelet normal count. In these trials, it was observed as well a significant reduction in the incidence of aTTP[rx] as well as a significant reduction in the median time to response of about 39%. However, as caplacizumab does not target autoimmune response, relapses were observed after treatment discontinuation.[rx]
The last clinical trial prior to approval showed the production of a platelet count of more than 150,000 per MCL after the cessation of plasma exchange therapy for 5 days as well as a reduction of patient recurrent thrombotic thrombocytopenic purpura and of disease-related death during treatment.[rx]
Ristocetin cofactor (RICO) activity was used to assess vWF activity. Subcutaneous doses of caplacizumab-yhdp at greater than or equal to the approved recommended dosage to healthy subjects and patients with aTTP decreased RICO activity levels to below 20% approximately hours post-dose. RICO activity returned to baseline values within 7 days of drug discontinuation. Caplacizumab-yhdp decreased vWF antigen and factor VIII:C levels. These reductions were transient and returned to baseline upon cessation of treatment.
Indications
- Capacizumab is approved for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP) in conjunction with plasma exchange and immunosuppression in patients 18 years or older.[rx]
- aTTP is a rare autoimmune condition presented by a disruption of blood clotting order which is translated into systemic microvascular thrombosis leading to profound thrombocytopenia, hemolytic anemia, and organ ischemia. It is caused by the production of autoantibodies against ADAMTS-13 which is the protein in charge of cleaving the von-Willebrand factor. The lack of this process produces the generation of ultra-large von Willebrand multimers that bind to platelets and form microthrombi and causing thromboembolic complications.[rx]
- Previously, bevacizumab was under review for the prevention of thrombosis in high-risk patients with acute coronary syndrome undergoing percutaneous coronary intervention but this indication was withdrawn.[rx]
- Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
- Treatment of patients with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange and immunosuppressive therapy
Use in Cancer
Caplacizumab-yhdp is approved to treat:
- Acquired thrombotic thrombocytopenic purpura (aTTP) in adults. It is used with plasma exchange and immunosuppressive therapy.
Contraindication
- contraindicated in patients with a previous severe hypersensitivity reaction to caplacizumab-yhdp or to any of the excipients. Hypersensitivity reactions have included urticaria
Dosage
Strengths: yhdp 11 mg
Thrombocytopenic Purpura
Initial dose:
- First day of treatment: 11 mg bolus IV injection at least 15 minutes prior to plasma exchange followed by an 11 mg subcutaneous injection after completion of plasma exchange on Day
Maintenance dose:
- Subsequent days of treatment during daily plasma exchange: 11 mg subcutaneous injection once a day following plasma exchange
- Treatment after plasma exchange period: 11 mg subcutaneous injection once a day continuing for 30 days following the last daily plasma exchange. If after initial treatment course sign(s) of persistent underlying disease such as suppressed ADAMTS13 activity levels remain present, treatment may be extended for a maximum of 28 days.
- Discontinue this drug if the patient experiences more than 2 recurrences of acquired thrombotic thrombocytopenic purpura (aTTP) during treatment with this drug.
- Withhold this drug 7 days prior to elective surgery, dental procedures, or other invasive interventions.
Side Effects
The Most Common
- headache
- extreme tiredness
- back pain
- muscle pain
- tingling, prickling, or numb feeling on the skin
- itching near the spot the medication was injected
- shortness of breath
- fever
- hives
- heavy bleeding that won’t stop including bleeding from rectum, vagina, nose, gums or place where the medication was injected
- vomiting blood
- red, or black, tarry stools
- blood in urine
- sudden severe headache, nausea, vomiting
- sudden, sharp abdominal pain, nausea, vomiting
- frequent, painful, or urgent urination
More Common
- easy bruising or bleeding (nosebleeds, bleeding gums);
- unusual vaginal bleeding;
- any bleeding that will not stop; or
- signs of stomach bleeding–bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds.
- nosebleeds, bleeding gums; or
- headache.
Rare
- hives,
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- easy bruising,
- unusual bleeding (nosebleeds, bleeding gums),
- unusual vaginal bleeding,
- any bleeding that will not stop,
- bloody or tarry stools,
- coughing up blood, and
- vomit that looks like coffee grounds
Interaction
| DRUG | INTERACTION |
|---|---|
| Abciximab | The risk or severity of bleeding can be increased when Caplacizumab is combined with Abciximab. |
| Abrocitinib | The risk or severity of bleeding and thrombocytopenia can be increased when Caplacizumab is combined with Abrocitinib. |
| Aceclofenac | The risk or severity of bleeding can be increased when Aceclofenac is combined with Caplacizumab. |
| Acemetacin | The risk or severity of bleeding can be increased when Acemetacin is combined with Caplacizumab. |
| Acenocoumarol | The risk or severity of bleeding can be increased when Caplacizumab is combined with Acenocoumarol. |
| Acetylsalicylic acid | Acetylsalicylic acid may increase the antiplatelet activities of Caplacizumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Caplacizumab. |
| Aducanumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Aducanumab. |
| Alclofenac | The risk or severity of bleeding can be increased when Alclofenac is combined with Caplacizumab. |
| Aldesleukin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Aldesleukin. |
| Alemtuzumab | The risk or severity of bleeding can be increased when Caplacizumab is combined with Alemtuzumab. |
| Alirocumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Alirocumab. |
| Alteplase | The risk or severity of bleeding can be increased when Caplacizumab is combined with Alteplase. |
| Altretamine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Altretamine. |
| Aminophenazone | The risk or severity of bleeding can be increased when Aminophenazone is combined with Caplacizumab. |
| Aminosalicylic acid | The risk or severity of bleeding can be increased when Caplacizumab is combined with Aminosalicylic acid. |
| Amivantamab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Amivantamab. |
| Amsacrine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Amsacrine. |
| Anagrelide | Anagrelide may increase the antiplatelet activities of Caplacizumab. |
| Ancrod | The risk or severity of bleeding can be increased when Caplacizumab is combined with Ancrod. |
| Anifrolumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Anifrolumab. |
| Anistreplase | The risk or severity of bleeding can be increased when Caplacizumab is combined with Anistreplase. |
| Ansuvimab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ansuvimab. |
| Anthrax immune | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Anthrax immune globulin human. |
| Antilymphocyte | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Antilymphocyte immunoglobulin (horse). |
| Antipyrine | The risk or severity of bleeding can be increased when Antipyrine is combined with Caplacizumab. |
| Antithrombin Alfa | The risk or severity of bleeding can be increased when Caplacizumab is combined with Antithrombin Alfa. |
| Antithrombin III human | The risk or severity of bleeding can be increased when Caplacizumab is combined with Antithrombin III human. |
| Antithymocyte | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Caplacizumab. |
| Antrafenine | The risk or severity of bleeding can be increased when Antrafenine is combined with Caplacizumab. |
| Apixaban | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Apixaban. |
| Ardeparin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Ardeparin. |
| Argatroban | The risk or severity of bleeding can be increased when Caplacizumab is combined with Argatroban. |
| Arsenic trioxide | The risk or severity of bleeding can be increased when Caplacizumab is combined with Arsenic trioxide. |
| Asfotase alfa | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Asfotase alfa. |
| Atezolizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Atezolizumab. |
| Atoltivimab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Atoltivimab. |
| Avelumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Avelumab. |
| Azacitidine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Azacitidine. |
| Balsalazide | The risk or severity of bleeding can be increased when Balsalazide is combined with Caplacizumab. |
| Bamlanivimab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Bamlanivimab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Caplacizumab. |
| Bebtelovimab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Bebtelovimab. |
| Belantamab mafodotin | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Belantamab mafodotin. |
| Belimumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Belimumab. |
| Belinostat | The risk or severity of bleeding can be increased when Caplacizumab is combined with Belinostat. |
| Bemiparin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Bemiparin. |
| Bendamustine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Bendamustine. |
| Benorilate | The risk or severity of bleeding can be increased when Benorilate is combined with Caplacizumab. |
| Benoxaprofen | The risk or severity of bleeding can be increased when Benoxaprofen is combined with Caplacizumab. |
| Benralizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Benralizumab. |
| Benzydamine | The risk or severity of bleeding can be increased when Benzydamine is combined with Caplacizumab. |
| Besilesomab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Besilesomab. |
| Betrixaban | The risk or severity of bleeding can be increased when Caplacizumab is combined with Betrixaban. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Caplacizumab. |
| Bexarotene | The risk or severity of bleeding can be increased when Caplacizumab is combined with Bexarotene. |
| Bezlotoxumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Bezlotoxumab. |
| Bimekizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Bimekizumab. |
| Bismuth subsalicylate | The risk or severity of bleeding can be increased when Caplacizumab is combined with Bismuth subsalicylate. |
| Bivalirudin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Bivalirudin. |
| Blinatumomab | The risk or severity of bleeding can be increased when Caplacizumab is combined with Blinatumomab. |
| Bortezomib | The risk or severity of bleeding can be increased when Caplacizumab is combined with Bortezomib. |
| Bosutinib | The risk or severity of bleeding can be increased when Caplacizumab is combined with Bosutinib. |
| Brentuximab vedotin | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Brentuximab vedotin. |
| Brodalumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Brodalumab. |
| Brolucizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Brolucizumab. |
| Bumadizone | The risk or severity of bleeding can be increased when Bumadizone is combined with Caplacizumab. |
| Burosumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Burosumab. |
| Busulfan | The risk or severity of bleeding can be increased when Caplacizumab is combined with Busulfan. |
| Cabazitaxel | The risk or severity of bleeding can be increased when Caplacizumab is combined with Cabazitaxel. |
| Canakinumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Canakinumab. |
| Cangrelor | The risk or severity of bleeding can be increased when Caplacizumab is combined with Cangrelor. |
| Capecitabine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Capecitabine. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Caplacizumab. |
| Carbamazepine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Carbamazepine. |
| Carboplatin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Carboplatin. |
| Carfilzomib | The risk or severity of bleeding can be increased when Caplacizumab is combined with Carfilzomib. |
| Carmustine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Carmustine. |
| Carprofen | The risk or severity of bleeding can be increased when Carprofen is combined with Caplacizumab. |
| Casirivimab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Casirivimab. |
| Catumaxomab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Catumaxomab. |
| Celecoxib | The risk or severity of bleeding can be increased when Celecoxib is combined with Caplacizumab. |
| Cemiplimab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Cemiplimab. |
| Certolizumab pegol | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Certolizumab pegol. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Caplacizumab. |
| Chenodeoxycholic acid | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Chenodeoxycholic acid. |
| Chlorambucil | The risk or severity of bleeding can be increased when Caplacizumab is combined with Chlorambucil. |
| Chloramphenicol | The risk or severity of bleeding can be increased when Caplacizumab is combined with Chloramphenicol. |
| Cholic Acid | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Cholic Acid. |
| Choline magnesium trisalicylate | The risk or severity of bleeding can be increased when Choline magnesium trisalicylate is combined with Caplacizumab. |
| Choline salicylate | The risk or severity of bleeding can be increased when Caplacizumab is combined with Choline salicylate. |
| Cilgavimab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Cilgavimab. |
| Cilostazol | Cilostazol may increase the antiplatelet activities of Caplacizumab. |
| Cisplatin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Cisplatin. |
| Citalopram | The risk or severity of hemorrhage can be increased when Citalopram is combined with Caplacizumab. |
| Cladribine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Cladribine. |
| Clofarabine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Clofarabine. |
| Clopidogrel | Clopidogrel may increase the antiplatelet activities of Caplacizumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Caplacizumab. |
| Cyclophosphamide | The risk or severity of bleeding can be increased when Caplacizumab is combined with Cyclophosphamide. |
| Cytarabine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Cytarabine. |
| Dabigatran | The risk or severity of bleeding can be increased when Caplacizumab is combined with Dabigatran. |
| Dabigatran etexilate | Caplacizumab may increase the anticoagulant activities of Dabigatran etexilate. |
| Dacarbazine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Dacarbazine. |
| Dactinomycin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Dactinomycin. |
| Dalteparin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Dalteparin. |
| Danaparoid | The risk or severity of bleeding can be increased when Caplacizumab is combined with Danaparoid. |
| Daratumumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Daratumumab. |
| Dasatinib | Dasatinib may increase the anticoagulant activities of Caplacizumab. |
| Daunorubicin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Daunorubicin. |
| Decitabine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Decitabine. |
| Defibrotide | The risk or severity of bleeding can be increased when Caplacizumab is combined with Defibrotide. |
| Dehydrocholic acid | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Dehydrocholic acid. |
| Denosumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Denosumab. |
| Deoxycholic acid | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Deoxycholic acid. |
| Desirudin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Desirudin. |
| Desvenlafaxine | The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Caplacizumab. |
| Dexibuprofen | The risk or severity of bleeding can be increased when Dexibuprofen is combined with Caplacizumab. |
| Dexketoprofen | The risk or severity of bleeding can be increased when Dexketoprofen is combined with Caplacizumab. |
| Dexrazoxane | The risk or severity of bleeding can be increased when Caplacizumab is combined with Dexrazoxane. |
| Dextran | The risk or severity of bleeding can be increased when Caplacizumab is combined with Dextran. |
| Diclofenac | The risk or severity of bleeding can be increased when Diclofenac is combined with Caplacizumab. |
| Dicoumarol | The risk or severity of bleeding can be increased when Caplacizumab is combined with Dicoumarol. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Caplacizumab. |
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Caplacizumab. |
| Diflunisal | The risk or severity of bleeding can be increased when Diflunisal is combined with Caplacizumab. |
| Digoxin Immune | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Caplacizumab. |
| Dinutuximab | The risk or severity of bleeding can be increased when Caplacizumab is combined with Dinutuximab. |
| Dipyridamole | The risk or severity of bleeding can be increased when Caplacizumab is combined with Dipyridamole. |
| Docetaxel | The risk or severity of bleeding can be increased when Caplacizumab is combined with Docetaxel. |
| Dostarlimab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Dostarlimab. |
| Doxorubicin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Doxorubicin. |
| Drotrecogin alfa | The risk or severity of bleeding can be increased when Caplacizumab is combined with Drotrecogin alfa. |
| Dulaglutide | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Dulaglutide. |
| Duloxetine | The risk or severity of hemorrhage can be increased when Duloxetine is combined with Caplacizumab. |
| Dupilumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Dupilumab. |
| Durvalumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Durvalumab. |
| Ebola Zaire vaccine | The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Caplacizumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Caplacizumab. |
| Edetic acid | The risk or severity of bleeding can be increased when Caplacizumab is combined with Edetic acid. |
| Edoxaban | The risk or severity of bleeding can be increased when Caplacizumab is combined with Edoxaban. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Caplacizumab. |
| Eflapegrastim | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Eflapegrastim. |
| Eftrenonacog alfa | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Eftrenonacog alfa. |
| Elotuzumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Elotuzumab. |
| Emapalumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Emapalumab. |
| Emicizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Emicizumab. |
| Enoxaparin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Enoxaparin. |
| Epirubicin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Epirubicin. |
| Epoprostenol | The risk or severity of bleeding can be increased when Caplacizumab is combined with Epoprostenol. |
| Eptifibatide | Eptifibatide may increase the antiplatelet activities of Caplacizumab. |
| Eptinezumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Eptinezumab. |
| Erenumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Erenumab. |
| Eribulin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Eribulin. |
| Escitalopram | The risk or severity of bleeding can be increased when Escitalopram is combined with Caplacizumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Caplacizumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Caplacizumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Caplacizumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Caplacizumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Caplacizumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Caplacizumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Caplacizumab. |
| Estriol | Estriol may increase the thrombogenic activities of Caplacizumab. |
| Estrone | Estrone may increase the thrombogenic activities of Caplacizumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Caplacizumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Caplacizumab. |
| Etodolac | The risk or severity of bleeding can be increased when Etodolac is combined with Caplacizumab. |
| Etoposide | The risk or severity of bleeding can be increased when Caplacizumab is combined with Etoposide. |
| Etoricoxib | The risk or severity of bleeding can be increased when Etoricoxib is combined with Caplacizumab. |
| Everolimus | The risk or severity of bleeding can be increased when Caplacizumab is combined with Everolimus. |
| Evolocumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Evolocumab. |
| Fanolesomab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Fanolesomab. |
| Fenbufen | The risk or severity of bleeding can be increased when Fenbufen is combined with Caplacizumab. |
| Fenoprofen | The risk or severity of bleeding can be increased when Fenoprofen is combined with Caplacizumab. |
| Floctafenine | The risk or severity of bleeding can be increased when Floctafenine is combined with Caplacizumab. |
| Floxuridine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Floxuridine. |
| Flucytosine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Flucytosine. |
| Fludarabine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Fludarabine. |
| Fluindione | The risk or severity of bleeding can be increased when Caplacizumab is combined with Fluindione. |
| Fluorouracil | The risk or severity of bleeding can be increased when Caplacizumab is combined with Fluorouracil. |
| Fluoxetine | The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Caplacizumab. |
| Flurbiprofen | The risk or severity of bleeding can be increased when Flurbiprofen is combined with Caplacizumab. |
| Fluvoxamine | The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Caplacizumab. |
| Fondaparinux | The risk or severity of bleeding can be increased when Caplacizumab is combined with Fondaparinux. |
| Fremanezumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Fremanezumab. |
| Galcanezumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Galcanezumab. |
| Gemcitabine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Gemcitabine. |
| Gemtuzumab ozogamicin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Gemtuzumab ozogamicin. |
| Ginkgo biloba | Ginkgo biloba may increase the antiplatelet activities of Caplacizumab. |
| Glucosamine | Glucosamine may increase the antiplatelet activities of Caplacizumab. |
| Glycol salicylate | The risk or severity of bleeding can be increased when Glycol salicylate is combined with Caplacizumab. |
| Golimumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Golimumab. |
| Guselkumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Guselkumab. |
| Heparin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Heparin. |
| Ibalizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ibalizumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ibritumomab tiuxetan. |
| Ibrutinib | The risk or severity of adverse effects can be increased when Ibrutinib is combined with Caplacizumab. |
| Ibuprofen | The risk or severity of bleeding can be increased when Ibuprofen is combined with Caplacizumab. |
| Icosapent | The risk or severity of bleeding can be increased when Icosapent is combined with Caplacizumab. |
| Icosapent ethyl | Caplacizumab may increase the antiplatelet activities of Icosapent ethyl. |
| Idarubicin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Idarubicin. |
| Idarucizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Idarucizumab. |
| Ifosfamide | The risk or severity of bleeding can be increased when Caplacizumab is combined with Ifosfamide. |
| Iloprost | Iloprost may increase the antiplatelet activities of Caplacizumab. |
| Imatinib | The risk or severity of bleeding can be increased when Caplacizumab is combined with Imatinib. |
| Imdevimab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Imdevimab. |
| Indomethacin | The risk or severity of bleeding can be increased when Indomethacin is combined with Caplacizumab. |
| Inebilizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Inebilizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Caplacizumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Caplacizumab. |
| Interferon alfa-2a | The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon alfa-2a. |
| Interferon alfa-2b | The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon alfa-2b. |
| Interferon alfa-n1 | The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon alfa-n1. |
| Interferon alfa-n3 | The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon alfa-n3. |
| Interferon alfacon-1 | The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon alfacon-1. |
| Interferon beta-1b | The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon beta-1b. |
| Interferon gamma-1b | The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon gamma-1b. |
| Ipilimumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ipilimumab. |
| Irinotecan | The risk or severity of bleeding can be increased when Caplacizumab is combined with Irinotecan. |
| Isatuximab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Isatuximab. |
| Isocarboxazid | The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Caplacizumab. |
| Isoxicam | The risk or severity of bleeding can be increased when Isoxicam is combined with Caplacizumab. |
| Ixabepilone | The risk or severity of bleeding can be increased when Caplacizumab is combined with Ixabepilone. |
| Ixekizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ixekizumab. |
| Ketoprofen | The risk or severity of bleeding can be increased when Ketoprofen is combined with Caplacizumab. |
| Ketorolac | The risk or severity of bleeding can be increased when Ketorolac is combined with Caplacizumab. |
| Lanadelumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Lanadelumab. |
| Lenalidomide | The risk or severity of bleeding can be increased when Caplacizumab is combined with Lenalidomide. |
| Lepirudin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Lepirudin. |
| Levomilnacipran | The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Caplacizumab. |
| Linezolid | The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Caplacizumab. |
| Lomustine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Lomustine. |
| Loncastuximab tesirine | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Loncastuximab tesirine. |
| Lornoxicam | The risk or severity of bleeding can be increased when Lornoxicam is combined with Caplacizumab. |
| Loxoprofen | The risk or severity of bleeding can be increased when Loxoprofen is combined with Caplacizumab. |
| Lumiracoxib | The risk or severity of bleeding can be increased when Lumiracoxib is combined with Caplacizumab. |
| Maftivimab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Maftivimab. |
| Margetuximab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Margetuximab. |
| Mechlorethamine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Mechlorethamine. |
| Meclofenamic acid | The risk or severity of bleeding can be increased when Meclofenamic acid is combined with Caplacizumab. |
| Mefenamic acid | The risk or severity of bleeding can be increased when Mefenamic acid is combined with Caplacizumab. |
| Meloxicam | The risk or severity of bleeding can be increased when Meloxicam is combined with Caplacizumab. |
| Melphalan | The risk or severity of bleeding can be increased when Caplacizumab is combined with Melphalan. |
| Menthyl salicylate | The risk or severity of bleeding can be increased when Menthyl salicylate is combined with Caplacizumab. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Mepolizumab. |
| Mercaptopurine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Mercaptopurine. |
| Mesalazine | The risk or severity of bleeding can be increased when Mesalazine is combined with Caplacizumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Caplacizumab. |
| Methimazole | The risk or severity of bleeding can be increased when Caplacizumab is combined with Methimazole. |
| Methotrexate | The risk or severity of bleeding can be increased when Caplacizumab is combined with Methotrexate. |
| Methyl salicylate | The risk or severity of bleeding can be increased when Caplacizumab is combined with Methyl salicylate. |
| Methylene blue | The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Caplacizumab. |
| Milnacipran | The risk or severity of hemorrhage can be increased when Milnacipran is combined with Caplacizumab. |
| Minaprine | The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Caplacizumab. |
| Mitomycin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Mitomycin. |
| Mitoxantrone | The risk or severity of bleeding can be increased when Caplacizumab is combined with Mitoxantrone. |
| Moclobemide | The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Caplacizumab. |
| Mogamulizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Mogamulizumab. |
| Mosunetuzumab | The risk or severity of bleeding can be increased when Caplacizumab is combined with Mosunetuzumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Caplacizumab. |
| Nabumetone | The risk or severity of bleeding can be increased when Nabumetone is combined with Caplacizumab. |
| Nadroparin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Nadroparin. |
| Naproxen | The risk or severity of bleeding can be increased when Naproxen is combined with Caplacizumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Caplacizumab. |
| Necitumumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Necitumumab. |
| Nefazodone | The risk or severity of hemorrhage can be increased when Nefazodone is combined with Caplacizumab. |
| Nelarabine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Nelarabine. |
| Nialamide | The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Caplacizumab. |
| Nilotinib | The risk or severity of bleeding can be increased when Caplacizumab is combined with Nilotinib. |
| Nimesulide | The risk or severity of bleeding can be increased when Nimesulide is combined with Caplacizumab. |
| Nivolumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Nivolumab. |
| Obeticholic acid | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Obeticholic acid. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Caplacizumab. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Obinutuzumab. |
| Ocrelizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ocrelizumab. |
| Odesivimab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Odesivimab. |
| Ofatumumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ofatumumab. |
| Olaparib | The risk or severity of bleeding can be increased when Caplacizumab is combined with Olaparib. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Caplacizumab. |
| Olsalazine | The risk or severity of bleeding can be increased when Olsalazine is combined with Caplacizumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Caplacizumab. |
| Omega-3 fatty acids | Omega-3 fatty acids may increase the antiplatelet activities of Caplacizumab. |
| Omega-3-acid eth | The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Caplacizumab. |
| Oxaliplatin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Oxaliplatin. |
| Oxaprozin | The risk or severity of bleeding can be increased when Oxaprozin is combined with Caplacizumab. |
| Oxyphenbutazone | The risk or severity of bleeding can be increased when Oxyphenbutazone is combined with Caplacizumab. |
| Paclitaxel | The risk or severity of bleeding can be increased when Caplacizumab is combined with Paclitaxel. |
| Padeliporfin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Padeliporfin. |
| Palbociclib | The risk or severity of bleeding can be increased when Caplacizumab is combined with Palbociclib. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Caplacizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Caplacizumab. |
| Parecoxib | The risk or severity of bleeding can be increased when Parecoxib is combined with Caplacizumab. |
| Pargyline | The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Caplacizumab. |
| Parnaparin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Parnaparin. |
| Paroxetine | The risk or severity of hemorrhage can be increased when Paroxetine is combined with Caplacizumab. |
| Peginterferon alfa-2a | The risk or severity of bleeding can be increased when Caplacizumab is combined with Peginterferon alfa-2a. |
| Peginterferon alfa-2b | The risk or severity of bleeding can be increased when Caplacizumab is combined with Peginterferon alfa-2b. |
| Peginterferon beta-1a | The risk or severity of bleeding can be increased when Caplacizumab is combined with Peginterferon beta-1a. |
| Pembrolizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Pembrolizumab. |
| Pemetrexed | The risk or severity of bleeding can be increased when Caplacizumab is combined with Pemetrexed. |
| Penicillamine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Penicillamine. |
| Pentosan polysulfate | The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Caplacizumab. |
| Pentostatin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Pentostatin. |
| Pentoxifylline | Pentoxifylline may increase the antiplatelet activities of Caplacizumab. |
| Pertuzumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Pertuzumab. |
| Phenelzine | The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Caplacizumab. |
| Phenindione | The risk or severity of bleeding can be increased when Caplacizumab is combined with Phenindione. |
| Phenprocoumon | The risk or severity of bleeding can be increased when Caplacizumab is combined with Phenprocoumon. |
| Phenyl aminosalicylate | The risk or severity of bleeding can be increased when Caplacizumab is combined with Phenyl aminosalicylate. |
| Phenylalanine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Phenylalanine. |
| Phenylbutazone | The risk or severity of bleeding can be increased when Phenylbutazone is combined with Caplacizumab. |
| Piroxicam | The risk or severity of bleeding can be increased when Piroxicam is combined with Caplacizumab. |
| Polatuzumab vedotin | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Polatuzumab vedotin. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Caplacizumab. |
| Pomalidomide | The risk or severity of bleeding can be increased when Caplacizumab is combined with Pomalidomide. |
| Ponatinib | The risk or severity of bleeding can be increased when Caplacizumab is combined with Ponatinib. |
| Prasugrel | The risk or severity of bleeding can be increased when Caplacizumab is combined with Prasugrel. |
| Procaine | The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Caplacizumab. |
| Procarbazine | The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Caplacizumab. |
| Propylthiouracil | The risk or severity of bleeding can be increased when Caplacizumab is combined with Propylthiouracil. |
| Protein C | The risk or severity of bleeding can be increased when Caplacizumab is combined with Protein C. |
| Protein S human | The risk or severity of bleeding can be increased when Caplacizumab is combined with Protein S human. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Caplacizumab. |
| Raltitrexed | The risk or severity of bleeding can be increased when Caplacizumab is combined with Raltitrexed. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Caplacizumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Caplacizumab. |
| Rasagiline | The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Caplacizumab. |
| Ravulizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ravulizumab. |
| Raxibacumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Raxibacumab. |
| Reslizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Reslizumab. |
| Reteplase | The risk or severity of bleeding can be increased when Caplacizumab is combined with Reteplase. |
| Reviparin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Reviparin. |
| Risankizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Risankizumab. |
| Rituximab | The risk or severity of bleeding can be increased when Caplacizumab is combined with Rituximab. |
| Rivaroxaban | Caplacizumab may increase the anticoagulant activities of Rivaroxaban. |
| Rofecoxib | The risk or severity of bleeding can be increased when Rofecoxib is combined with Caplacizumab. |
| Romosozumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Romosozumab. |
| Ropeginterferon | The risk or severity of bleeding can be increased when Caplacizumab is combined with Ropeginterferon alfa-2b. |
| Ruxolitinib | The risk or severity of bleeding can be increased when Caplacizumab is combined with Ruxolitinib. |
| Sacituzumab govitecan | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Sacituzumab govitecan. |
| Safinamide | The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Caplacizumab. |
| Salicylamide | The risk or severity of bleeding can be increased when Salicylamide is combined with Caplacizumab. |
| Salicylic acid | The risk or severity of bleeding can be increased when Salicylic acid is combined with Caplacizumab. |
| Salsalate | The risk or severity of bleeding can be increased when Salsalate is combined with Caplacizumab. |
| Sarilumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Sarilumab. |
| Secukinumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Secukinumab. |
| Selegiline | The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Caplacizumab. |
| Sertraline | The risk or severity of bleeding can be increased when Sertraline is combined with Caplacizumab. |
| Sibutramine | The risk or severity of hemorrhage can be increased when Sibutramine is combined with Caplacizumab. |
| Siltuximab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Siltuximab. |
| Sirolimus | The risk or severity of bleeding can be increased when Caplacizumab is combined with Sirolimus. |
| Sodium citrate | The risk or severity of bleeding can be increased when Caplacizumab is combined with Sodium citrate. |
| Sorafenib | The risk or severity of bleeding can be increased when Caplacizumab is combined with Sorafenib. |
| Sotrovimab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Sotrovimab. |
| Spesolimab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Spesolimab. |
| Streptokinase | The risk or severity of bleeding can be increased when Caplacizumab is combined with Streptokinase. |
| Streptozocin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Streptozocin. |
| Sulesomab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Sulesomab. |
| Sulfasalazine | The risk or severity of bleeding can be increased when Sulfasalazine is combined with Caplacizumab. |
| Sulfinpyrazone | Sulfinpyrazone may increase the antiplatelet activities of Caplacizumab. |
| Sulindac | The risk or severity of bleeding can be increased when Sulindac is combined with Caplacizumab. |
| Sulodexide | The risk or severity of bleeding can be increased when Caplacizumab is combined with Sulodexide. |
| Sutimlimab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Sutimlimab. |
| Synthetic Conjugated | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Caplacizumab. |
| Synthetic Conjugated | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Caplacizumab. |
| Tacrolimus | The risk or severity of bleeding can be increased when Caplacizumab is combined with Tacrolimus. |
| Tafasitamab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tafasitamab. |
| Taurocholic acid | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Taurocholic acid. |
| Tauroursodeoxycholic | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tauroursodeoxycholic acid. |
| Tedizolid phosphate | The risk or severity of bleeding can be increased when Caplacizumab is combined with Tedizolid phosphate. |
| Temozolomide | The risk or severity of bleeding can be increased when Caplacizumab is combined with Temozolomide. |
| Temsirolimus | The risk or severity of bleeding can be increased when Caplacizumab is combined with Temsirolimus. |
| Tenecteplase | The risk or severity of bleeding can be increased when Caplacizumab is combined with Tenecteplase. |
| Teniposide | The risk or severity of bleeding can be increased when Caplacizumab is combined with Teniposide. |
| Tenoxicam | The risk or severity of bleeding can be increased when Tenoxicam is combined with Caplacizumab. |
| Tetanus immune globulin, | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tetanus immune globulin, human. |
| Tezepelumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tezepelumab. |
| Thalidomide | The risk or severity of bleeding can be increased when Caplacizumab is combined with Thalidomide. |
| Thiotepa | The risk or severity of bleeding can be increased when Caplacizumab is combined with Thiotepa. |
| Tiaprofenic acid | The risk or severity of bleeding can be increased when Tiaprofenic acid is combined with Caplacizumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Caplacizumab. |
| Ticagrelor | The risk or severity of bleeding can be increased when Caplacizumab is combined with Ticagrelor. |
| Ticlopidine | Ticlopidine may increase the antiplatelet activities of Caplacizumab. |
| Tildrakizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tildrakizumab. |
| Tinzaparin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Tinzaparin. |
| Tioguanine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Tioguanine. |
| Tipranavir | Tipranavir may increase the antiplatelet activities of Caplacizumab. |
| Tirofiban | Tirofiban may increase the antiplatelet activities of Caplacizumab. |
| Tisotumab vedotin | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tisotumab vedotin. |
| Tixagevimab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tixagevimab. |
| Tocilizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tocilizumab. |
| Tofacitinib | The risk or severity of bleeding can be increased when Caplacizumab is combined with Tofacitinib. |
| Tolfenamic acid | The risk or severity of bleeding can be increased when Tolfenamic acid is combined with Caplacizumab. |
| Tolmetin | The risk or severity of bleeding can be increased when Tolmetin is combined with Caplacizumab. |
| Topotecan | The risk or severity of bleeding can be increased when Caplacizumab is combined with Topotecan. |
| Tositumomab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tositumomab. |
| Trabectedin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Trabectedin. |
| Tralokinumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tralokinumab. |
| Tranylcypromine | The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Caplacizumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Caplacizumab. |
| Trastuzumab deruxtecan | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Trastuzumab deruxtecan. |
| Trastuzumab | The risk or severity of bleeding can be increased when Caplacizumab is combined with Trastuzumab emtansine. |
| Trazodone | The risk or severity of bleeding can be increased when Trazodone is combined with Caplacizumab. |
| Tremelimumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tremelimumab. |
| Treprostinil | Treprostinil may increase the antiplatelet activities of Caplacizumab. |
| Triflusal | The risk or severity of bleeding can be increased when Caplacizumab is combined with Triflusal. |
| Urokinase | Caplacizumab may increase the anticoagulant activities of Urokinase. |
| Ursodeoxycholic acid | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ursodeoxycholic acid. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Caplacizumab. |
| Valdecoxib | The risk or severity of bleeding can be increased when Valdecoxib is combined with Caplacizumab. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Vedolizumab. |
| Venlafaxine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Venlafaxine. |
| Vinblastine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Vinblastine. |
| Vindesine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Vindesine. |
| Vinorelbine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Vinorelbine. |
| Vitamin E | Vitamin E may increase the antiplatelet activities of Caplacizumab. |
| Vorapaxar | The risk or severity of bleeding can be increased when Caplacizumab is combined with Vorapaxar. |
| Vorinostat | The risk or severity of bleeding can be increased when Caplacizumab is combined with Vorinostat. |
| Vortioxetine | The risk or severity of bleeding can be increased when Vortioxetine is combined with Caplacizumab. |
| Warfarin | The risk or severity of bleeding can be increased when Caplacizumab is combined with Warfarin. |
| Ximelagatran | The risk or severity of bleeding can be increased when Caplacizumab is combined with Ximelagatran. |
| Zidovudine | The risk or severity of bleeding can be increased when Caplacizumab is combined with Zidovudine. |
| Zimelidine | The risk or severity of hemorrhage can be increased when Zimelidine is combined with Caplacizumab. |
Pregnancy and Lactation
US FDA pregnancy category: Not assigned.
Pregnancy
There are no available data on CABLIVI use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, there are potential risks of hemorrhage in the mother and fetus associated with the use of CABLIVI. In animal reproduction studies, there was no evidence of adverse developmental outcomes with intramuscular administration of caplacizumab-yhdp during organogenesis in guinea pigs at exposures approximately 30 times the AUC in humans at the recommended subcutaneous injection dose of 11 mg (see Data).
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background rate of major birth defects and miscarriage in the indicated population is unknown. In the U.S. general population, the estimated background rate of major birth defects and
miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Lactation
There is no information regarding the presence of caplacizumab-yhdp in human milk, the effects on the breastfed child or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for CABLIVI and any potential adverse effects on the breastfed child from CABLIVI, or from the underlying maternal condition
How should this medicine be used?
Caplacizumab-yhdp comes as a powder to be dissolved in liquid and given by intravenous (into the vein) or subcutaneous (under the skin) injection. It is usually given on the first day of treatment as an intravenous injection at least 15 minutes before plasma exchange, and then again as a subcutaneous injection after plasma exchange is finished. After the first day of treatment, it is usually given as a once-daily subcutaneous injection following plasma exchange for as long as you receive plasma exchange therapy, and then once daily for an additional 30 to 58 days after stopping plasma exchange therapy. Use caplacizumab-yhdp at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Use caplacizumab-yhdp exactly as directed. Do not use more or less of it or use it more often than prescribed by your doctor.
Your doctor may allow you or a caregiver to perform the injections at home. Ask your doctor or pharmacist to show you or the person who will be performing the injections how to prepare and inject caplacizumab-yhdp. Before you use caplacizumab-yhdp injection yourself for the first time, read the written instructions that come with it. Ask your pharmacist or doctor for a copy of the manufacturer’s instructions for use information for the patient.
You should inject caplacizumab-yhdp injection subcutaneously in the abdominal (stomach) area but avoid your navel and the area 2 inches (5 centimeters) around it. Do not inject in the same spot two days in a row.
Dispose of used needles, syringes, and vials in a puncture-resistant container. Talk to your doctor or pharmacist about how to dispose of the puncture-resistant container.
What special precautions should I follow?
Before receiving caplacizumab-yhdp,
- tell your doctor and pharmacist if you are allergic to caplacizumab-yhdp, any other medications, or any of the ingredients in caplacizumab-yhdp injection. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: apixaban (Eliquis), clopidogrel (Plavix), dabigatran (Pradaxa), dipyridamole (Persantine, in Aggrenox), edoxaban (Savaysa), enoxaparin (Lovenox), fondaparinux (Arixtra), heparin, prasugrel (Effient), rivaroxaban (Xarelto), ticagrelor (Brilinta), or warfarin (Coumadin, Jantoven). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- tell your doctor if you have or have ever had hemophilia (a genetic disorder in which the body can’t stop bleeding properly) or other bleeding problems, or liver disease.
- tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. If you become pregnant while receiving caplacizumab-yhdp, call your doctor.
- if you are having surgery, including dental surgery, tell the doctor or dentist that you are using caplacizumab-yhdp. Your doctor or dentist may tell you not to use caplacizumab-yhdp for 7 days before the surgery.
References